Literature DB >> 8903849

Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis.

A R Glabinski1, M Tani, V K Tuohy, R J Tuthill, R M Ransohoff.   

Abstract

Central nervous system (CNS) expression of two chemokine mRNAs, encoding monocyte chemoattractant protein-1 (MCP-1) and IFN-gamma-inducible protein (IP-10), was previously shown to be closely related to the onset of clinical signs of murine experimental autoimmune encephalomyelitis (EAE). Chemokine mRNAs accumulated in a striking, transient burst within astrocytes, near inflammatory leukocyte infiltrates. It remained unclear if chemokines functioned to initiate leukocyte entry into CNS tissues, or to amplify the intrathecal inflammatory reaction. To address this issue, we determined the expression of chemokine mRNAs at the earliest evidence of CNS immune-mediated inflammation. For these experiments, mice were sacrificed in pairs at varying times after immunization. Only one member of each pair was symptomatic for EAE at the time of sacrifice. Symptom presence correlated well with histological inflammation at the time of sacrifice. RNA was prepared from two CNS sites, brain and spinal cord, and expression of chemokine mRNAs was analyzed by a sensitive and quantitative reverse transcriptase/polymerase chain reaction dot-blot hybridization assay. CNS expressions of MCP-1 and IP-10 gene were correlated tightly with histological inflammation; indeed, chemokine expression was never detected in the absence of leukocyte infiltrates. In situ hybridizations showed that astrocytes expressed chemokine transcripts. These findings provide new information about mechanisms controlling chemokine mRNA expression during immune-mediated inflammation in EAE and are consistent with a role for chemokines as amplifiers of CNS inflammatory reactions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8903849     DOI: 10.1006/brbi.1995.1030

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  39 in total

Review 1.  Chemokines and central nervous system disorders.

Authors:  W J Karpus
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

Review 2.  Regulation of experimental autoimmune encephalomyelitis by chemokines and chemokine receptors.

Authors:  Adam Elhofy; Kevin J Kennedy; Brian T Fife; William J Karpus
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 3.  [Chemokine--possible new options for the treatment of multiple sclerosis].

Authors:  C Trebst; R M Ransohoff; A Windhagen; M Stangel
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

Review 4.  Control of autoimmune CNS inflammation by astrocytes.

Authors:  Veit Rothhammer; Francisco J Quintana
Journal:  Semin Immunopathol       Date:  2015-07-30       Impact factor: 9.623

5.  Gamma interferon signaling in macrophage lineage cells regulates central nervous system inflammation and chemokine production.

Authors:  Adora A Lin; Pulak K Tripathi; Allyson Sholl; Michael B Jordan; David A Hildeman
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

6.  Immunology: In the beginning.

Authors:  Richard M Ransohoff
Journal:  Nature       Date:  2009-11-05       Impact factor: 49.962

7.  Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis.

Authors:  A R Glabinski; M Tani; R M Strieter; V K Tuohy; R M Ransohoff
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

Review 8.  Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks.

Authors:  Bridgette D Semple; Thomas Kossmann; Maria Cristina Morganti-Kossmann
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

9.  The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function.

Authors:  Jia Ni; Yi-Na Zhu; Xiang-Gen Zhong; Yu Ding; Li-Fei Hou; Xian-Kun Tong; Wei Tang; Shiro Ono; Yi-Fu Yang; Jian-Ping Zuo
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

10.  Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide.

Authors:  Ray Chui; Katerina Dorovini-Zis
Journal:  J Neuroinflammation       Date:  2010-01-04       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.